Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

CBLL vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PMI Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–5 Matrix Metrics)

PMI Overall Winner 6-Pillar Tally: CBLL 2 – 2 PMI (2 Tie) Matrix Metrics: CBLL 5 – 4 PMI

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over CeriBell, Inc. (CBLL) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). CBLL carries a Unified Composite Score of 59.7/100 (HOLD) at $25.75 (N/M Forward P/E, -69.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Composite vs. Pillar Nuance: While CBLL currently prints a higher short-term Unified Composite Score (59.7/100 HOLD vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -69.8% operating margin) and revenue trajectory (+38.6% vs. +29.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CBLL vs PMI
CBLL NASDAQ
CeriBell, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$25.75
+0.47% 1D
Market Cap $995.3M
TTM Revenue $109M
Forward P/E N/M
Beta / 30D Vol 1.08β · 41% Vol
Unified Composite Score
59.7 / 100 HOLD
Tech 51.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $26.87 · SMA50: $25.66
PMI NYSE American Head-to-Head Winner
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (CBLL 2 – 2 PMI)

Columns: Metric · CBLL · PMI
1. Valuation Multiples PMI
Forward P/E N/M N/M
Trailing P/E N/M 2.9x
PEG Ratio N/M N/M
EV / Revenue 9.2x 3.2x
2. Growth & Scale CBLL
Revenue Growth (YoY) +29.9% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $109M $6.3M
Market Cap $995.3M $17.1M
3. Profitability & Quality CBLL
Gross Margin 89.3% 18.6%
Operating Margin -69.8% -248.1%
Net Profit Margin -68.0% 0.0%
Return on Equity (ROE) -52.5% 0.0%
4. Balance Sheet & Cash Flow PMI
Cash Generation (TTM) -$75M EBITDA -$17M
Cash Flow Margin -68.8% EBITDA Mgn N/A
Net Cash / Leverage $3.03 Book/Sh · -52.5% ROE $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 67.5% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CBLL (5) vs PMI (4)
Institutional Metric CBLL PMI Criterion Row Edge
Market Capitalization
Scale
$995.3M $17.1M Larger Scale CBLL
Trailing P/E Ratio
Valuation
N/M 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+29.9% +38.6% Higher Growth PMI
Operating Margin (TTM)
Profitability
-69.8% -248.1% Higher Margin CBLL
Net Profit Margin
Profitability
-68.0% 0.0% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
-52.5% 0.0% Higher ROE PMI
52-Week Range Position
Momentum
81% ($13–$29) 34% ($0–$18) Stronger Trend CBLL
Beta / 30D Volatility
Risk Regime
1.08β · 41% Vol 54.06β · 134% Vol Lower Realized Risk CBLL
Unified Institutional Score
Composite Signal
59.7 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite CBLL
Trailing 12M Revenue (USD)
Operating Scale
$109M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.3% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.2x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M EBITDA ($3.03 Book/Sh · -52.5% ROE) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CBLL +29.46 pp
CBLL: -5.12% · PMI: -34.58%
3M Horizon PMI +89.86 pp
CBLL: +6.4% · PMI: +96.26%
6M Horizon PMI +3385.6 pp
CBLL: +53.73% · PMI: +3439.33%
1Y Horizon PMI +52.95 pp
CBLL: +95.08% · PMI: +148.03%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CBLL vs PMI. Trailing 12-month operating profitability (CBLL -69.8% vs PMI -248.1%) and valuation multiples (CBLL N/M vs PMI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CBLL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$109M
Gross Margin89.3%
Op. Margin-69.8%
ROE / Fwd P/E-52.5% · N/M
PMI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.3M
Gross Margin18.6%
Op. Margin-248.1%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CBLL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 67.5%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CBLL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CBLL Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $995.3M market capitalization and -69.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CBLL vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, Picard Medical, Inc. (PMI) is the stronger overall head-to-head candidate over CeriBell, Inc. (CBLL) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow). CBLL carries a Unified Composite Score of 59.7/100 (HOLD) at $25.75 (N/M Forward P/E, -69.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While CBLL currently prints a higher short-term Unified Composite Score (59.7/100 HOLD vs. PMI 48.4/100 HOLD), PMI captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (-248.1% vs. -69.8% operating margin) and revenue trajectory (+38.6% vs. +29.9% YoY).

CBLL leads the Growth & Scale pillar: CBLL posts +29.9% YoY revenue growth and +0.0% YoY earnings growth on $109M TTM revenue (89.3% gross margin, -69.8% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). On trailing 12-month operating scale, CBLL generates $109M in USD-normalized revenue versus $6.3M for PMI. In operating R&D and SG&A reinvestment, CBLL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

PMI screens cheaper on headline valuation multiples. CBLL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-68.8% EBITDA margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBLL (-52.5% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CBLL carries 67.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.08β · 41% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.